Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

"Nivolumab (BMS-936558-01), 480 mg intravenous (every 4 weeks)~Treatment must be within 7 days of the last dose of radiation."

"BMS-986253 (Anti-IL-8), 2,400 mg intravenous (every 2 weeks)~Treatment must be within 7 days of the last dose of radiation."

"Stereotactic Body Radiotherapy (SBRT) (varying doses)~SBRT: Initial Dose fractionation of 3 or 5 fractions of radiation as determined by the location of the metastases to be irradiated, to at least 1 but no more than 4 metastatic lesions. There will be a minimum of 40 hours between treatments for an individual metastasis.~SBRT must be completed within a 14-day window, separate from the screening phase. Treatment with nivolumab and BMS-986253 must be within 7 days of the last dose of radiation."